

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market 2018, Forecast to 2023

<https://marketpublishers.com/r/GA594DC6DF7EN.html>

Date: June 2018

Pages: 119

Price: US\$ 4,880.00 (Single User License)

ID: GA594DC6DF7EN

Abstracts

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Scope of the Report:

This report focuses on the Checkpoint Inhibitors for Treating Cancer in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.

Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most

patients, the price is unbearable.

The worldwide market for Checkpoint Inhibitors for Treating Cancer is expected to grow at a CAGR of roughly 28.0% over the next five years, will reach 20600 million US\$ in 2023, from 4690 million US\$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Bristol-Myers Squibb(BMS)

Merck

Roche

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

PD-1 Inhibitors

PD-L1 Inhibitors

CTLA-4 Inhibitors

Market Segment by Applications, can be divided into

Melanoma Treatment

Bladder Cancer Treatment

Other

There are 15 Chapters to deeply display the global Checkpoint Inhibitors for Treating Cancer market.

Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with sales, revenue, and price of Checkpoint Inhibitors for Treating Cancer, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Checkpoint Inhibitors for Treating Cancer, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Checkpoint Inhibitors for Treating Cancer market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Contents

1 MARKET OVERVIEW

- 1.1 Checkpoint Inhibitors for Treating Cancer Introduction
- 1.2 Market Analysis by Type
 - 1.2.1 PD-1 Inhibitors
 - 1.2.2 PD-L1 Inhibitors
 - 1.2.3 CTLA-4 Inhibitors
- 1.3 Market Analysis by Applications
 - 1.3.1 Melanoma Treatment
 - 1.3.2 Bladder Cancer Treatment
 - 1.3.3 Other
- 1.4 Market Analysis by Regions
 - 1.4.1 North America (United States, Canada and Mexico)
 - 1.4.1.1 United States Market States and Outlook (2013-2023)
 - 1.4.1.2 Canada Market States and Outlook (2013-2023)
 - 1.4.1.3 Mexico Market States and Outlook (2013-2023)
 - 1.4.2 Europe (Germany, France, UK, Russia and Italy)
 - 1.4.2.1 Germany Market States and Outlook (2013-2023)
 - 1.4.2.2 France Market States and Outlook (2013-2023)
 - 1.4.2.3 UK Market States and Outlook (2013-2023)
 - 1.4.2.4 Russia Market States and Outlook (2013-2023)
 - 1.4.2.5 Italy Market States and Outlook (2013-2023)
 - 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
 - 1.4.3.1 China Market States and Outlook (2013-2023)
 - 1.4.3.2 Japan Market States and Outlook (2013-2023)
 - 1.4.3.3 Korea Market States and Outlook (2013-2023)
 - 1.4.3.4 India Market States and Outlook (2013-2023)
 - 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
 - 1.4.4 South America, Middle East and Africa
 - 1.4.4.1 Brazil Market States and Outlook (2013-2023)
 - 1.4.4.2 Egypt Market States and Outlook (2013-2023)
 - 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
 - 1.4.4.4 South Africa Market States and Outlook (2013-2023)
 - 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
- 1.5 Market Dynamics
 - 1.5.1 Market Opportunities
 - 1.5.2 Market Risk

1.5.3 Market Driving Force

2 MANUFACTURERS PROFILES

2.1 Bristol-Myers Squibb(BMS)

2.1.1 Business Overview

2.1.1.1 Bristol-Myers Squibb(BMS) Description

2.1.1.2 Bristol-Myers Squibb(BMS) Headquarter, Main Business and Finance

Overview

2.1.2 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Introduction

2.1.2.1 Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions and Major Competitors

2.1.2.2 Checkpoint Inhibitors for Treating Cancer Product Information

2.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.1 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.1.3.2 Global Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Market Share in 2017

2.2 Merck

2.2.1 Business Overview

2.2.1.1 Merck Description

2.2.1.2 Merck Headquarter, Main Business and Finance Overview

2.2.2 Merck Checkpoint Inhibitors for Treating Cancer Product Introduction

2.2.2.1 Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions and Major Competitors

2.2.2.2 Checkpoint Inhibitors for Treating Cancer Product Information

2.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.1 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2.3.2 Global Merck Checkpoint Inhibitors for Treating Cancer Market Share in 2017

2.3 Roche

2.3.1 Business Overview

2.3.1.1 Roche Description

2.3.1.2 Roche Headquarter, Main Business and Finance Overview

2.3.2 Roche Checkpoint Inhibitors for Treating Cancer Product Introduction

2.3.2.1 Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions

and Major Competitors

2.3.2.2 Checkpoint Inhibitors for Treating Cancer Product Information

2.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.1 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3.3.2 Global Roche Checkpoint Inhibitors for Treating Cancer Market Share in 2017

3 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET COMPETITION, BY MANUFACTURER

3.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Manufacturer (2016-2017)

3.3 Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturer (2016-2017)

3.4 Market Concentration Rate

3.4.1 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2017

3.4.2 Top 5 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2017

3.5 Market Competition Trend

4 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET ANALYSIS BY REGIONS

4.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions

4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2013-2018)

4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2013-2018)

4.2 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2013-2018)

4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2013-2018)

4.5 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2013-2018)

5 NORTH AMERICA CHECKPOINT INHIBITORS FOR TREATING CANCER BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

5.1 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries

5.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

5.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

5.1.3 United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

5.1.4 Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

5.1.5 Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

5.2 North America Checkpoint Inhibitors for Treating Cancer Sales and Revenue (Value) by Manufacturers (2016-2017)

5.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2017)

5.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2017)

5.3 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

5.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Type (2013-2018)

5.3.2 North America Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Type (2013-2018)

5.4 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Application (2013-2018)

5.4.1 North America Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Application (2013-2018)

5.4.2 North America Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Application (2013-2018)

6 EUROPE CHECKPOINT INHIBITORS FOR TREATING CANCER BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

6.1 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries

6.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

6.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

6.1.3 Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

6.1.4 UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

6.1.5 France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

6.1.6 Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

6.1.7 Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

6.2 Europe Checkpoint Inhibitors for Treating Cancer Sales and Revenue (Value) by Manufacturers (2016-2017)

6.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2017)

6.2.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2017)

6.3 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

6.3.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Type (2013-2018)

6.3.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Type (2013-2018)

6.4 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Application (2013-2018)

6.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Application (2013-2018)

6.4.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Application (2013-2018)

7 ASIA-PACIFIC CHECKPOINT INHIBITORS FOR TREATING CANCER BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

7.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

7.1.3 China Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

7.1.4 Japan Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

7.1.5 Korea Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

7.1.6 India Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

7.1.7 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

7.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Revenue (Value) by Manufacturers (2016-2017)

7.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2017)

7.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2017)

7.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

7.3.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Type (2013-2018)

7.3.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Type (2013-2018)

7.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Application (2013-2018)

7.4.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Application (2013-2018)

7.4.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Application (2013-2018)

8 SOUTH AMERICA CHECKPOINT INHIBITORS FOR TREATING CANCER BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

8.1 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and

Market Share by Countries

8.1.1 South America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

8.1.2 South America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

8.1.3 Brazil Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

8.1.4 Argentina Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

8.1.5 Colombia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

8.2 South America Checkpoint Inhibitors for Treating Cancer Sales and Revenue (Value) by Manufacturers (2016-2017)

8.2.1 South America Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2017)

8.2.2 South America Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2017)

8.3 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

8.3.1 South America Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Type (2013-2018)

8.3.2 South America Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Type (2013-2018)

8.4 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Application (2013-2018)

8.4.1 South America Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Application (2013-2018)

8.4.2 South America Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Application (2013-2018)

9 MIDDLE EAST AND AFRICA CHECKPOINT INHIBITORS FOR TREATING CANCER BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

9.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

9.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

9.1.3 Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

9.1.4 UAE Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

9.1.5 Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

9.1.6 Nigeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

9.1.7 South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

9.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Revenue (Value) by Manufacturers (2016-2017)

9.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2017)

9.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2017)

9.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

9.3.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Type (2013-2018)

9.3.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Type (2013-2018)

9.4 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Application (2013-2018)

9.4.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Sales Share by Application (2013-2018)

9.4.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Revenue Share by Application (2013-2018)

10 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET SEGMENT BY TYPE

10.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2013-2018)

10.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2013-2018)

10.2 PD-1 Inhibitors Sales Growth and Price

- 10.2.1 Global PD-1 Inhibitors Sales Growth (2013-2018)
- 10.2.2 Global PD-1 Inhibitors Price (2013-2018)
- 10.3 PD-L1 Inhibitors Sales Growth and Price
 - 10.3.1 Global PD-L1 Inhibitors Sales Growth (2013-2018)
 - 10.3.2 Global PD-L1 Inhibitors Price (2013-2018)
- 10.4 CTLA-4 Inhibitors Sales Growth and Price
 - 10.4.1 Global CTLA-4 Inhibitors Sales Growth (2013-2018)
 - 10.4.2 Global CTLA-4 Inhibitors Price (2013-2018)

11 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET SEGMENT BY APPLICATION

- 11.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2013-2018)
- 11.2 Melanoma Treatment Sales Growth (2013-2018)
- 11.3 Bladder Cancer Treatment Sales Growth (2013-2018)
- 11.4 Other Sales Growth (2013-2018)

12 CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET FORECAST (2018-2023)

- 12.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2018-2023)
- 12.2 Checkpoint Inhibitors for Treating Cancer Market Forecast by Regions (2018-2023)
 - 12.2.1 North America Checkpoint Inhibitors for Treating Cancer Market Forecast (2018-2023)
 - 12.2.2 Europe Checkpoint Inhibitors for Treating Cancer Market Forecast (2018-2023)
 - 12.2.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast (2018-2023)
 - 12.2.4 South America Checkpoint Inhibitors for Treating Cancer Market Forecast (2018-2023)
 - 12.2.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Forecast (2018-2023)
- 12.3 Checkpoint Inhibitors for Treating Cancer Market Forecast by Type (2018-2023)
 - 12.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2018-2023)
 - 12.3.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Type (2018-2023)
- 12.4 Checkpoint Inhibitors for Treating Cancer Market Forecast by Application

(2018-2023)

12.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application

(2018-2023)

12.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application (2018-2023)

13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 RESEARCH FINDINGS AND CONCLUSION

15 APPENDIX

15.1 Methodology

15.2 Data Source

List Of Tables

LIST OF TABLES AND FIGURES

Figure Checkpoint Inhibitors for Treating Cancer Picture

Table Product Specifications of Checkpoint Inhibitors for Treating Cancer

Figure Global Checkpoint Inhibitors for Treating Cancer CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)

Figure Global Checkpoint Inhibitors for Treating Cancer CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)

Figure Global Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Types in 2017

Figure PD-1 Inhibitors Picture

Table Major Manufacturers of PD-1 Inhibitors

Figure PD-L1 Inhibitors Picture

Table Major Manufacturers of PD-L1 Inhibitors

Figure CTLA-4 Inhibitors Picture

Table Major Manufacturers of CTLA-4 Inhibitors

Figure Checkpoint Inhibitors for Treating Cancer Sales Market Share by Applications in 2017

Figure Melanoma Treatment Picture

Figure Bladder Cancer Treatment Picture

Figure Other Picture

Figure United States Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Canada Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Mexico Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Germany Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure France Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure UK Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Russia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Italy Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure China Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Japan Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Korea Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure India Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Brazil Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Egypt Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure South Africa Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Figure Nigeria Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2013-2023)

Table Bristol-Myers Squibb(BMS) Headquarter, Established, Main Business and Finance Overview (2017)

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions and Major Competitors

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Figure Global Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Market Share in 2017

Figure Global Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Revenue Market Share in 2017

Table Merck Headquarter, Established, Main Business and Finance Overview (2017)

Table Merck Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions and Major Competitors

Table Merck Checkpoint Inhibitors for Treating Cancer Product

Table Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Figure Global Merck Checkpoint Inhibitors for Treating Cancer Sales Market Share in 2017

Figure Global Merck Checkpoint Inhibitors for Treating Cancer Revenue Market Share in 2017

Table Roche Headquarter, Established, Main Business and Finance Overview (2017)

Table Roche Checkpoint Inhibitors for Treating Cancer Production Bases, Sales Regions and Major Competitors

Table Roche Checkpoint Inhibitors for Treating Cancer Product

Table Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Figure Global Roche Checkpoint Inhibitors for Treating Cancer Sales Market Share in 2017

Figure Global Roche Checkpoint Inhibitors for Treating Cancer Revenue Market Share in 2017

Table Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2017)

Figure Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2016

Figure Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2017

Table Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2016-2017)

Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2016

Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2017

Table Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturer (2016-2017)

Figure Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2017

Figure Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2017

Figure Global Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Global Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2013-2018)

Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions in 2013

Figure Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions in 2017

Figure North America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Figure South America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure South America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2013-2018)

Figure North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2013

Figure North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2017

Table North America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2013-2018)

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share

by Countries in 2013

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2017

Figure United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2017)

Figure North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2016

Figure North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2017

Table North America Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2016-2017)

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2016

Figure North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2017

Table North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Revenue by Application (2013-2018)

Table North America Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2013-2018)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2016

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2017

Figure Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2016

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2017

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2016-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2016

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2017

Table Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales Share by Application
(2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue by Application
(2013-2018)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue Share by Application
(2013-2018)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate
(2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Countries
(2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by
Countries (2013-2018)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by
Countries 2017

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Countries
(2013-2018)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by
Countries 2017

Figure China Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate
(2013-2018)

Figure Japan Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate
(2013-2018)

Figure Korea Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate
(2013-2018)

Figure India Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate
(2013-2018)

Figure Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate
(2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer
(2016-2017)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by
Manufacturer in 2016

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by
Manufacturer in 2017

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer
(2016-2017)

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by
Manufacturer in 2016

Figure Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by

Manufacturer in 2017

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Application (2013-2018)

Table Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2013-2018)

Figure South America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2013-2018)

Figure South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2017

Table South America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2013-2018)

Figure South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2017

Figure Brazil Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Argentina Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Colombia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2017)

Figure South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by

Manufacturer in 2016

Figure South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2017

Table South America Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2016-2017)

Figure South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2016

Figure South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2017

Table South America Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales by Application (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Revenue by Application (2013-2018)

Table South America Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2013-2018)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Countries (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2013-2018)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2017

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2013

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2017

Figure Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure UAE Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure Nigeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Figure South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2017)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2016

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2017

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2016-2017)

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2016

Figure Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2017

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Application (2013-2018)

Table Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Share

by Application (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type
(2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type
(2013-2018)

Figure Global PD-1 Inhibitors Sales Growth (2013-2018)

Figure Global PD-1 Inhibitors Price (2013-2018)

Figure Global PD-L1 Inhibitors Sales Growth (2013-2018)

Figure Global PD-L1 Inhibitors Price (2013-2018)

Figure Global CTLA-4 Inhibitors Sales Growth (2013-2018)

Figure Global CTLA-4 Inhibitors Price (2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales by Application
(2013-2018)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application
(2013-2018)

Figure Global Melanoma Treatment Sales Growth (2013-2018)

Figure Global Bladder Cancer Treatment Sales Growth (2013-2018)

Figure Global Other Sales Growth (2013-2018)

Figure Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth
Rate (2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions
(2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by
Regions (2018-2023)

Figure North America Sales Checkpoint Inhibitors for Treating Cancer Market Forecast
(2018-2023)

Figure Europe Sales Checkpoint Inhibitors for Treating Cancer Market Forecast
(2018-2023)

Figure Asia-Pacific Sales Checkpoint Inhibitors for Treating Cancer Market Forecast
(2018-2023)

Figure South America Sales Checkpoint Inhibitors for Treating Cancer Market Forecast
(2018-2023)

Figure Middle East and Africa Sales Checkpoint Inhibitors for Treating Cancer Market
Forecast (2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type
(2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Type

(2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application

(2018-2023)

Table Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by
Application (2018-2023)

Table Distributors/Traders/ Dealers List

I would like to order

Product name: Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa)
Checkpoint Inhibitors for Treating Cancer Market 2018, Forecast to 2023

Product link: <https://marketpublishers.com/r/GA594DC6DF7EN.html>

Price: US\$ 4,880.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA594DC6DF7EN.html>